Go Backs
HomeCategoriesStatesCheck Your Home
Go Backs

Track product recalls and safety alerts from CPSC, FDA, NHTSA, and USDA. Stay informed and keep your family safe.

Browse

  • Categories
  • States
  • Check Your Home
  • Risk Levels

Agencies

  • CPSC
  • FDA Food
  • FDA Drug
  • FDA Device
  • FDA Veterinary
  • NHTSA
  • USDA

Company

  • About
  • FAQ
  • Contact
  • Terms of Service
  • Privacy Policy

Recall data is sourced from official U.S. government agencies (CPSC, FDA, NHTSA, USDA) and processed using AI to improve readability. This site is not affiliated with or endorsed by any government agency. Always refer to the original agency notice for authoritative information.

© 2026 Go Backs. All rights reserved.

Medium RiskFDA Drug
Medications & Supplements/Prescription Drugs

The General Hospital Corporation: Fludeoxyglucose F 18 Injection Recalled for Lack of Assurance of Sterility

Agency Publication Date: February 24, 2021
Share:
Sign in to monitor this recall

Summary

The General Hospital Corporation is recalling approximately 50 vials of Fludeoxyglucose F 18 Injection (20-300 mCi/mL). This prescription medication, which was manufactured by the Massachusetts General Hospital PET Center, is being recalled because of a lack of assurance of sterility. While no specific injuries or incidents have been reported, a lack of sterility in an injectable drug can lead to serious infections or other life-threatening complications. This recall affects 50 mL glass vials distributed to a single direct account in February 2021.

Risk

If an injectable drug is not sterile, it can introduce bacteria or other contaminants directly into the bloodstream or tissues, potentially causing severe systemic infections or sepsis.

What You Should Do

  1. Identify if you have the affected product by checking the label for Fludeoxyglucose F 18 Injection (20-300 mCi/mL) in 50 mL glass vials with NDC 76318-334-50.
  2. Check the packaging for Lot # P01-021721 with an expiration date of 02/17/2021.
  3. Immediately contact your healthcare provider or pharmacist for guidance if you have been administered this lot or have it in your possession.
  4. Return any unused product to the pharmacy or the place of purchase for a refund.
  5. Contact The General Hospital Corporation at 55 Fruit St, Boston, MA 02114 for further instructions regarding this recall.
  6. For additional questions, contact the FDA Consumer Complaint hotline at 1-888-723-3332 (1-888-SAFEFDA) or visit www.fda.gov/safety/recalls.

Your Remedy Options

💰Full Refund

Healthcare provider consultation and product refund.

How to: Contact your healthcare provider or pharmacist for guidance. Return any unused product to the pharmacy for a refund

Affected Products

Product: Fludeoxyglucose F 18 Injection, 20-300 mCi/mL at End of Synthesis (EOS) Solution (50 mL glass vial)
Model:
NDC 76318-334-50
Recall #: D-0288-2021
Lot Numbers:
P01-021721 (exp 02/17/2021)
Date Ranges: 02/17/2021

Additional Information

Agency: Food and Drug Administration (FDA)
Event ID: 87384
Status: Resolved
Manufacturer: The General Hospital Corporation
Sold By: Direct account
Manufactured In: United States
Units Affected: 50 mL vial
Distributed To: Massachusetts

Were You Affected by This Recall?

If you or a family member were harmed by this recalled product, you may have legal rights. Consider consulting a consumer protection attorney to understand your options for compensation.

Find an Attorney

This is general information, not legal advice. Go Backs is not a law firm and does not provide legal services.

AI-Enhanced Content: The summary, action steps, and risk assessment on this page were generated by AI from official government recall data to improve readability. This is not legal or medical advice. Always refer to the official agency sources below for authoritative information.

Sources: FDA iRES · Raw API Response

openFDA Disclaimer: This recall information is sourced from the openFDA API. Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated. Refer to the openFDA terms of service for more information.